Oxygen Delivery Focus Sangart specializes in targeted oxygen delivery to ischemic tissues via a pegylated hemoglobin molecule (MP4), presenting a unique value proposition for collaborations in acute care, stroke, myocardial infarction, and organ preservation where perfusion and oxygenation are critical.

Clinical Differentiation With over 30 years of research refining MP4, Sangart offers an established platform for partners seeking innovative oxygenation therapies, potential co-development opportunities, and differentiation from traditional vasodilators or generic cell therapies.

Strategic Partnerships Small to mid-size biotech and pharmaceutical partnerships could leverage Sangart’s niche oxygen delivery technology to complement existing ischemia or reperfusion programs, enabling faster translation and expanded indications.

Growth Readiness The company’s modest employee base (52) and global remit imply agility and potential for scalable collaborations, including joint ventures, licensing of MP4, or milestone-based programs to accelerate market entry.

Tech & IP Leverage MP4 platform, combined with Sangart’s proprietary pegylation technology, offers defensible IP and potential for expansion into related oxygenation applications, creating opportunities for value-adding collaborations, grants, and alternate delivery modalities.